Avalo Therapeutics (AVTX) Non-Current Deferred Tax Liability (2017 - 2026)
Avalo Therapeutics posted quarterly Non-Current Deferred Tax Liability of $446000.0 for Q1 2026, up 60.43% year-on-year from $278000.0 in Q1 2025, and up 2.76% on a QoQ basis from $434000.0 in Q4 2025.
Avalo Therapeutics (AVTX) has 10 years of Non-Current Deferred Tax Liability data on file, last reported at $446000.0 in Q1 2026.
- For the quarter ending Q1 2026, Non-Current Deferred Tax Liability rose 60.43% year-over-year to $446000.0; the trailing twelve-month figure through Mar 2026 stood at $446000.0 (up 60.43% YoY), and the FY2025 full-year result was $434000.0, down 69.65% from the prior year.
- Non-Current Deferred Tax Liability for Q1 2026 stood at $446000.0, up from $434000.0 in the prior quarter.
- Across five years, Non-Current Deferred Tax Liability topped out at $1.4 million in Q4 2024 and bottomed at $122000.0 in Q1 2022.
- The 5-year median for Non-Current Deferred Tax Liability is $162000.0 (2024), against an average of $283294.1.
- The widest annual swing landed in 2024, when Non-Current Deferred Tax Liability jumped 822.58%; it then slumped 69.65% in 2025.
- A 5-year view of Non-Current Deferred Tax Liability shows it stood at $141000.0 in 2022, then gained by 9.93% to $155000.0 in 2023, then surged by 822.58% to $1.4 million in 2024, then plunged by 69.65% to $434000.0 in 2025, then gained by 2.76% to $446000.0 in 2026.
- The last three Non-Current Deferred Tax Liability figures came in at $446000.0 (Q1 2026), $434000.0 (Q4 2025), and $304000.0 (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Avalo Therapeutics | 317.29 Mn | 317.29 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 446,000.00 |
| Mar 31, 2026 | 446,000.00 |
| Dec 31, 2025 | 434,000.00 |
| Dec 31, 2025 | 434,000.00 |
| Sep 30, 2025 | 304,000.00 |
| Sep 30, 2025 | 304,000.00 |
| Jun 30, 2025 | 293,000.00 |
| Jun 30, 2025 | 293,000.00 |
| Mar 31, 2025 | 278,000.00 |
| Mar 31, 2025 | 278,000.00 |
| Dec 31, 2024 | 1.43 Mn |
| Dec 31, 2024 | 1.43 Mn |
| Sep 30, 2024 | 154,000.00 |
| Sep 30, 2024 | 154,000.00 |
| Jun 30, 2024 | 168,000.00 |
| Jun 30, 2024 | 168,000.00 |
| Mar 31, 2024 | 162,000.00 |
| Mar 31, 2024 | 162,000.00 |
| Dec 31, 2023 | 155,000.00 |
| Dec 31, 2023 | 155,000.00 |
| Sep 30, 2023 | 164,000.00 |
| Sep 30, 2023 | 164,000.00 |
| Jun 30, 2023 | 156,000.00 |
| Jun 30, 2023 | 156,000.00 |
| Mar 31, 2023 | 148,000.00 |
| Mar 31, 2023 | 148,000.00 |
| Dec 31, 2022 | 141,000.00 |
| Dec 31, 2022 | 141,000.00 |
| Sep 30, 2022 | 133,000.00 |
| Sep 30, 2022 | 133,000.00 |
| Jun 30, 2022 | 128,000.00 |
| Jun 30, 2022 | 128,000.00 |
| Mar 31, 2022 | 122,000.00 |
| Mar 31, 2022 | 122,000.00 |
| Dec 31, 2021 | 113,000.00 |
| Dec 31, 2021 | 113,000.00 |
| Sep 30, 2021 | 130,000.00 |
| Sep 30, 2021 | 130,000.00 |
| Jun 30, 2021 | 122,000.00 |
| Jun 30, 2021 | 122,000.00 |
| Mar 31, 2021 | 111,000.00 |
| Mar 31, 2021 | 111,000.00 |
| Dec 31, 2020 | 90,000.00 |
| Dec 31, 2020 | 90,000.00 |
| Sep 30, 2020 | 114,981.00 |
| Sep 30, 2020 | 114,981.00 |
| Mar 31, 2020 | 106,701.00 |
| Mar 31, 2020 | 106,701.00 |
| Dec 31, 2019 | 85,981.00 |
| Dec 31, 2019 | 85,981.00 |
| Sep 30, 2019 | 98,061.00 |
| Sep 30, 2019 | 98,061.00 |
| Jun 30, 2019 | 88,108.00 |
| Jun 30, 2019 | 88,108.00 |
| Mar 31, 2019 | 75,179.00 |
| Mar 31, 2019 | 75,179.00 |
| Dec 31, 2018 | 69,238.00 |
| Dec 31, 2018 | 69,238.00 |
| Sep 30, 2018 | 37,990.00 |
| Sep 30, 2018 | 37,990.00 |
| Jun 30, 2018 | 30,908.00 |
| Jun 30, 2018 | 30,908.00 |
| Mar 31, 2018 | 23,057.00 |
| Mar 31, 2018 | 23,057.00 |
| Dec 31, 2017 | 7,144.00 |
| Dec 31, 2017 | 7,144.00 |